About Us

BioSpeedia was founded by 2 renowned scientists from the Institut Pasteur in 2011: Evelyne Begaud, President and Yves Germani, Chief Scientific Officer.

Our clinical research is conducted at St-Priest-en-Jarez, France and clinical testing and quality control in Paris and St. Etienne, France. BioSpeedia is also in the process of relocating part of its overseas production to France.

Our sales and distribution, product registration, liasing with regulatory authorities, logistics and shipping is handled by our distribution arm, BioVitess Ltd. which is located in Belfast, UK.

All business in the United States, including registration, liaising with regulatory authorities, sales and distribution is handled by our subsidiary BioSpeedia LLC. We also have our subsidiary in Switerland, BioSpeedia International.

Institut pasteur

Nous sommes un spin-off de l’Institut Pasteur et disposons d’une licence nous donnant accès aux principaux réactifs.

SICPA

SICPA, brings its experience in secure authentication, here to make test certificates forgery-proof.

DELPHARM

We manufacture in France at the Delpharm Biotech plant in Lyon and have the only fully automated production line for “lateral flow” testing.

CHU

BioSpeedia has partnered with the CHU de St Etienne for the design and validation of rapid tests.

Company History

  • Founded in 2011

    The establishment of BioSpeedia

    After spending 3 decades at Institut Pasteur, Yves Germani and Evelyne Begaud, establish the Company as the official spin-off from the premier French Institute.

  • 2014

    Grant from Aide au Partenariat Technologique

  • 2017

    Developed fast and accurate lateral flow diagnostic kit to detect Neisseria meningitidis (Menincococcus)

    Developed a diagnostic kit to rapidly detect bacterial meningitis using spinal fluid and subsequently using urine samples.

  • 2018

    WHO approves MeningoSpeed detection kit in spinal fluid

  • 2020

    Received CE Mark for our SARS-CoV-2 rapid antibody test kit

    COVID19SEROSpeed-IgM-IgG Test is an immunochromatographic assay designed for the qualitative detection and differentiation of specific IgM and IgG antibodies to coronavirus 2019-nCoV or SARS-CoV-2 in human fingertip blood samples

  • 2020

    Seal of Excellence from H2020

    For COVID-19 Response

  • 2020

    Received CE Mark for our SARS-CoV-2 rapid antigen test kit

    COVID-19SPEEDAntigen Test is a colloidal gold enhanced double antibody sandwich immunoassay for qualitative determination of SARS-CoV-2 antigen in human nasal swabs.